Malondialdehyde and Uric Acid as Predictors of Adverse Outcome in Patients with Chronic Heart Failure
Joint Authors
Wojciechowska, Celina
Romuk, Ewa
Jacheć, Wojciech
Rozentryt, Piotr
Zemła-Woszek, Aleksandra
Momot, Alina
Buczkowska, Marta
Source
Oxidative Medicine and Cellular Longevity
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-15, 15 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-10-09
Country of Publication
Egypt
No. of Pages
15
Main Subjects
Abstract EN
In chronic heart failure (HF), some parameters of oxidative stress are correlated with disease severity.
The aim of this study was to evaluate the importance of oxidative stress biomarkers in prognostic risk stratification (death and combined endpoint: heart transplantation or death).
In 774 patients, aged 48-59 years, with chronic HF with reduced ejection fraction (median: 24.0 (20-29)%), parameters such as total antioxidant capacity, total oxidant status, oxidative stress index, and concentration of uric acid (UA), bilirubin, protein sulfhydryl groups (PSH), and malondialdehyde (MDA) were measured.
The parameters were assessed as predictive biomarkers of mortality and combined endpoint in a 1-year follow-up.
The multivariate Cox regression analysis was adjusted for other important clinical and laboratory prognostic markers.
Among all the oxidative stress markers examined in multivariate analysis, only MDA and UA were found to be independent predictors of death and combined endpoint.
Higher serum MDA concentration increased the risk of death by 103.0% (HR=2.103; 95% CI (1.330-3.325)) and of combined endpoint occurrence by 100% (HR=2.000; 95% CI (1.366-2.928)) per μmol/L.
Baseline levels of MDA in the 4th quartile were associated with an increased risk of death with a relative risk (RR) of 3.64 (95% CI (1.917 to 6.926), p<0.001) and RR of 2.71 (95% CI (1.551 to 4.739), p<0.001) for the occurrence of combined endpoint as compared to levels of MDA in the 1st quartile.
Higher serum UA concentration increased the risk of death by 2.1% (HR=1.021; 95% CI (1.005-1.038), p<0.001) and increased combined endpoint occurrence by 1.4% (HR=1.014; 95% CI (1.005-1.028), p<0.001), for every 10 μmol/L.
Baseline levels of UA in the 4th quartile were associated with an increased risk for death with a RR of 3.21 (95% CI (1.734 to 5.931)) and RR of 2.73 (95% CI (1.560 to 4.766)) for the occurrence of combined endpoint as compared to the levels of UA in the 1st quartile.
In patients with chronic HF, increased MDA and UA concentrations were independently related to poor prognosis in a 1-year follow-up.
American Psychological Association (APA)
Romuk, Ewa& Wojciechowska, Celina& Jacheć, Wojciech& Zemła-Woszek, Aleksandra& Momot, Alina& Buczkowska, Marta…[et al.]. 2019. Malondialdehyde and Uric Acid as Predictors of Adverse Outcome in Patients with Chronic Heart Failure. Oxidative Medicine and Cellular Longevity،Vol. 2019, no. 2019, pp.1-15.
https://search.emarefa.net/detail/BIM-1206262
Modern Language Association (MLA)
Romuk, Ewa…[et al.]. Malondialdehyde and Uric Acid as Predictors of Adverse Outcome in Patients with Chronic Heart Failure. Oxidative Medicine and Cellular Longevity No. 2019 (2019), pp.1-15.
https://search.emarefa.net/detail/BIM-1206262
American Medical Association (AMA)
Romuk, Ewa& Wojciechowska, Celina& Jacheć, Wojciech& Zemła-Woszek, Aleksandra& Momot, Alina& Buczkowska, Marta…[et al.]. Malondialdehyde and Uric Acid as Predictors of Adverse Outcome in Patients with Chronic Heart Failure. Oxidative Medicine and Cellular Longevity. 2019. Vol. 2019, no. 2019, pp.1-15.
https://search.emarefa.net/detail/BIM-1206262
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1206262